Stocks Health care VBIO
NASDAQ · Health careValion Bio, Inc. (VBIO)
It posted a net loss of $18.8M. In fiscal 2025 capital spending exceeded operating cash flow by $7M. At June 30, 2026 it held $2.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Valion Bio, Inc.
- Net worth
- Valion Bio, Inc. has a market value (market cap) of $11.7M at the latest share price, and shareholders' equity of $4.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2024 revenue was $780K (-33.7% year on year), with a net loss of $5.7M.
- Cash flow
- In fiscal 2025 operations used $7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Valion Bio, Inc. does
Valion Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VBIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$8.9M | -$7.84 | -$7M |
| 2024 | $780K | -$5.7M | -$19.68 | -$5.7M |
| 2023 | $1.2M | -$8.2M | -$176.80 | -$8.6M |
| 2022 | $1.8M | -$10.1M | -$1,773.44 | -$8.9M |
| 2022 | $1.3M | -$8.5M | -$4,143.71 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Valion Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026Other event 8-K
- October 2, 2026Preliminary proxy statement PRE 14A
- October 1, 2026Other event 8-K
- September 23, 2026Executive or director change8-KValion Bio appointed board member Dean Zikria as Interim Chief Executive Officer and announced board leadership changes.
- September 4, 2026Passive stake changed SCHEDULE 13G/A
- September 3, 2026Activist stake changed SCHEDULE 13D/A
- September 2, 2026Activist stake changed SCHEDULE 13D/A
- September 1, 2026
- August 27, 2026Activist stake changed SCHEDULE 13D/A
- August 27, 2026
Insider trades
What the people running Valion Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 18, 2026 | Wolf Lisa GCOO & CFO | Exercised options | 4 | - |
| September 18, 2026 | Wolf Lisa GCOO & CFO | Shares withheld for tax | 2 | $4.2 |
| June 18, 2026 | Wolf Lisa GChief Financial Officer | Exercised options | 92 | - |
| May 18, 2026 | Handley Michael KChief Executive Officer, Director | Exercised options | 2,206 | - |
| April 15, 2026 | Bolton SheryleDirector | Bought | 10,000 | $10.4K |
| April 1, 2026 | Valauri Christina RizopoulosDirector | Bought | 19,000 | $18K |
| March 18, 2026 | Wolf Lisa GChief Financial Officer | Exercised options | 92 | - |
| February 18, 2026 | Handley Michael KChief Operating Officer | Exercised options | 8,824 | - |
Who owns VBIO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Murchinson Ltd.13G, passive with 8 related filers | 9.99% | July 17, 2026 |
| 3i, LP13G, passive with 3 related filers | 9.9% | September 4, 2026 |
Largest institutional holders
Insiders
5 insiders reported holding 72,748 shares in total, about $36.6K at the last price.
| Holder | Shares |
|---|---|
| Ernst JenniferChief Executive Officer, Director | 32,691 |
| Valauri Christina RizopoulosDirector | 19,000 |
| Handley Michael KChief Executive Officer, Director | 11,030 |
| Bolton SheryleDirector | 10,000 |
| Wolf Lisa GCOO & CFO | 27 |
Questions about VBIO
What does Valion Bio, Inc. do?
Valion Bio, Inc. is a company in the Health care sector, listed on NASDAQ as VBIO. Its shares trade on NASDAQ under the ticker VBIO.
What is Valion Bio, Inc.'s net worth?
Valion Bio, Inc. has a market value (market cap) of $11.7M at the latest share price, and shareholders' equity of $4.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Valion Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $18.8M.
When did Valion Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from October 6, 2026.
Similar companies
Compare VBIO with
Follow VBIO
Get an email when Valion Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Valion Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.